ArticlePharmaceuticals (Basel, Switzerland)2017
Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison between
Article in Pharmaceuticals (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Head-to-head comparison ofScientific reports · 2022Trial
- Predictive value of interim ¹¹C-choline PET/CT for response to radium-223 in metastatic castration-resistant prostate cancer.EJNMMI research · 2026Article
- Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era.Medicina (Kaunas, Lithuania) · 2025Review
- Progress in Oligometastatic Prostate Cancer: Emerging Imaging Innovations and Therapeutic Approaches.Cancers · 2024Review
- [Diagnosis and staging of metastatic hormone-sensitive prostate cancer].Urologie (Heidelberg, Germany) · 2023Review
- Underlying Features of Prostate Cancer-Statistics, Risk Factors, and Emerging Methods for Its Diagnosis.Current oncology (Toronto, Ont.) · 2023Review
- Where Do We Stand in the Management of Oligometastatic Prostate Cancer? A Comprehensive Review.Cancers · 2022Review
- Emerging methods for prostate cancer imaging: evaluating cancer structure and metabolic alterations more clearly.Molecular oncology · 2021Review
- Article
- Volume matters and intensification is needed: emerging trends in the management of advanced prostate cancer.Drugs in context · 2021Review
- A prospective intra-individual comparison of [European journal of nuclear medicine and molecular imaging · 2021Article
- Recent advances of PET imaging in clinical radiation oncology.Radiation oncology (London, England) · 2020Review
- Direct comparison ofAsia Oceania journal of nuclear medicine & biology · 2020Article
- Article
- Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.Prostate cancer and prostatic diseases · 2019Review
- [The role of molecular imaging (PET-CT) in the diagnostic and treatment pf prostate cancer].Wiener medizinische Wochenschrift (1946) · 2019Review
- Randomized prospective phase III trial ofBMC cancer · 2019Article
- Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?Therapeutic advances in medical oncology · 2019Review
- Multimodal imaging for radiation therapy planning in patients with primary prostate cancer.Physics and imaging in radiation oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the difference between bone scan and PSMA-PET/CT for the detection of bone metastases in prostate cancer.
methodsThirty patients with bone metastases originating from prostate cancer were examined by
resultsIn the bone scans, visual and semiautomatic lesion detection showed similar results with an average of 19.4 and 17.8 detected bone lesion per patient. However, in PSMA-PET/CT, on average double the numbers of lesions (40.0) were detected. The largest differences were found in the thorax and pelvis, which can be explained by the advantages of tomographic imaging. Bland-Altman analysis showed greater differences in patients with large numbers of bone metastases.
conclusionNo significant difference was found when using semiautomatic analysis compared to visual reading for bone scans. Fewer bone metastases were detected in bone scans than in PSMA-PET/CT. However, in none of our patients would the difference have led to clinical consequences. Therefore, it seems that for patients undergoing PSMA-PET/CT, there is no need to perform additional bone scans if the appropriate PET/CT protocols are applied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.